Vaxcyte (PCVX) CMO Luis Jodar Receives Equity Awards

What Happened

Luis Jodar, Chief Medical Officer of Vaxcyte, received equity awards on September 4, 2026. The filing reports two grants: 52,632 restricted stock units (RSUs) and 88,254 derivative shares (stock option award), each acquired at $0. These are grants/awards (code A) — not open-market purchases or sales — and there was no immediate sale or cash exercise reported.

Key Details

• Transaction date: 2026-09-04; Form 4 filed: 2026-09-09 (appears filed after the typical 2-business-day window).
• RSUs: 52,632 shares granted at $0. Each RSU converts to one share of common stock upon vesting. (Footnote F1)
• Options/derivative: 88,254 shares granted as a derivative award at $0 (right to acquire shares subject to vesting). (Footnote F2)
• Vesting (per footnotes):
  • RSUs (F1): 1/4 vest on Sept 7, 2027, then 1/8 of the original award every six months thereafter, subject to continued service.
  • Options (F2): 1/4 vest on Aug 31, 2027, then 1/48 of the original award vests monthly thereafter, subject to continued service.
• Shares owned after the transaction: not specified in the provided filing text.
• Filing timeliness: The Form 4 was filed five days after the transaction date and therefore appears to be late relative to the usual 2-business-day filing requirement for insiders.

Context

• RSU grants and option awards at $0 are standard forms of executive compensation and do not reflect an immediate cash outlay or market purchase; they vest over time and become valuable only if the share price appreciates and vesting conditions are met.
• The derivative award represents the right to receive or purchase shares in the future per the vesting schedule; it does not mean shares were exercised or sold.
• These transactions are routine equity grants to executives and should be interpreted as compensation rather than a direct bullish or bearish market signal.